Influence of Factor V Leiden on susceptibility to and outcome from critical illness: A genetic association study

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Benfield, Thomas ^a,b   Ejrnæs, Karen ^a   Juul, Klaus ^c,d   Østergaard, Christian ^c   Helweg Larsen, Jannik ^d   Weis, Nina ^a   Munthe Fog, Lea ^d   Kronborg, Gitte ^a   Andersen, Marianne R ^a   Tybjærg Hansen, Anne ^b,d,e   Nordestgaard, Børge G ^b,c,e   Garred, Peter ^d  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Copenhagen University Hospital ^*  (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRITICAL ILLNESS; DEATH; ESCHERICHIA COLI INFECTION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GRAM NEGATIVE SEPSIS; HETEROZYGOTE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; COMPARATIVE STUDY; DENMARK; GENETIC POLYMORPHISM; GENETICS; GRAM NEGATIVE BACTERIUM; IMMUNOLOGY; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK ASSESSMENT; SEPSIS;

COHORT STUDIES; CRITICAL ILLNESS; DENMARK; FACTOR V; GRAM-NEGATIVE BACTERIA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEPSIS;

EID: 78149254617     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8899     Document Type: Article

References (26)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269-1276. 10.1016/S0140-6736(96)07493-4, 9142060.
2. Beaglehole R, Irwin A, Prentice T. The World Health Report: 2003: Shaping the Future 2003, World Health Organization.
3. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. National Vital Statistics Report 2004, 53(8). Hyattsville, Md., National Center for Health Statistics.
4. Bochud PY, Bochud M, Telenti A, Calandra T. Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis 2007, 7:531-542. 10.1016/S1473-3099(07)70185-8, 17646026.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67. 10.1038/369064a0, 8164741.
6. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004, 140:330-337.
7. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003, 101:20-30. 10.1182/blood-2002-01-0290, 12393635.
8. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003, 102:3085-3092. 10.1182/blood-2003-06-1789, 12869495.
9. Adamzik M, Frey UH, Riemann K, Sixt S, Lehmann N, Siffert W, Peters J. Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Crit Care Med 2008, 36:1776-1779. 10.1097/CCM.0b013e318174373d, 18496379.
10. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004, 32:S239-S246. 10.1097/01.CCM.0000126122.34119.D1, 15118525.
11. Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006, 34:2201-2206. 10.1097/01.CCM.0000228918.30931.E8, 16775574.
12. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009, 113:1358-1364. 10.1182/blood-2008-07-170506, 2637198, 19056689.
13. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999, 18:893-896. 10.1097/00006454-199910000-00011, 10530586.
14. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 2005, 192:1851-1857. 10.1086/497167, 16235188.
15. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998, 338:1577-1584. 10.1056/NEJM199805283382203, 9603795.
16. Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis 2007, 7:108. 10.1186/1471-2334-7-108, 2034565, 17877801.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
18. Garred P, Strom J, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003, 188:1394-1403. 10.1086/379044, 14593599.
19. Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine 2008, 26:3765-3771. 10.1016/j.vaccine.2008.04.040, 18513840.
20. Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, Skinhoj P, Garred P. Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis 2002, 185:1517-1520. 10.1086/340216, 11992290.
21. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002, 100:3-10. 10.1182/blood-2002-01-0111, 12070000.
22. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997, 336:399-403. 10.1056/NEJM199702063360602, 9010145.
23. Bergh FA, van Oeveren-Dybicz AM, Bon MA. Rapid single-tube genotyping of the factor V Leiden and prothrombin mutations by real-time PCR using dual-color detection. Clin Chem 2000, 46:1191-1195.
24. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainault J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
25. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618. 10.1056/NEJMoa041747, 15602021.
26. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006, 367:1075-1079. 10.1016/S0140-6736(06)68474-2, 16581406.